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Ciprofloxacin resistance in community- and
hospital-acquired Escherichia coli urinary
tract infections: a systematic review and
meta-analysis of observational studies
Oyebola Fasugba1*, Anne Gardner1, Brett G. Mitchell1,2 and George Mnatzaganian3

Abstract
Background: During the last decade the resistance rate of urinary Escherichia coli (E. coli) to fluoroquinolones such as
ciprofloxacin has increased. Systematic reviews of studies investigating ciprofloxacin resistance in community- and
hospital-acquired E. coli urinary tract infections (UTI) are absent. This study systematically reviewed the literature and
where appropriate, meta-analysed studies investigating ciprofloxacin resistance in community- and hospital-acquired
E. coli UTIs.
Methods: Observational studies published between 2004 and 2014 were identified through Medline, PubMed,
Embase, Cochrane, Scopus and Cinahl searches. Overall and sub-group pooled estimates of ciprofloxacin resistance
were evaluated using DerSimonian-Laird random-effects models. The I2 statistic was calculated to demonstrate the
degree of heterogeneity. Risk of bias among included studies was also investigated.
Results: Of the identified 1134 papers, 53 were eligible for inclusion, providing 54 studies for analysis with one paper
presenting both community and hospital studies. Compared to the community setting, resistance to ciprofloxacin was
significantly higher in the hospital setting (pooled resistance 0.38, 95 % CI 0.36-0.41 versus 0.27, 95 % CI 0.24-0.31 in
community-acquired UTIs, P < 0.001). Resistance significantly varied by region and country with the highest resistance
observed in developing countries. Similarly, a significant rise in resistance over time was seen in studies reporting on
community-acquired E. coli UTI.
Conclusions: Ciprofloxacin resistance in E. coli UTI is increasing and the use of this antimicrobial agent as empirical
therapy for UTI should be reconsidered. Policy restrictions on ciprofloxacin use should be enhanced especially in
developing countries without current regulations.
Keywords: Antimicrobial resistance, Escherichia coli, Urinary tract infection, Systematic review, Meta-analysis

Background
Urinary tract infections (UTI) are one of the most frequent
bacterial infections affecting people both in the community
and in hospitals [1]. It is estimated that about 150 million
people per annum are diagnosed with UTI worldwide [2].
A recent World Health Organisation (WHO) report on
antimicrobial resistance (AMR) surveillance specified nine
bacteria of international concern which are responsible for
* Correspondence: oyebola.fasugba@myacu.edu.au
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some of the most common infections in community and
hospital settings [3]. Escherichia coli (E. coli), the pathogen
most often implicated in UTIs, is listed as one of the nine.
In all six WHO regions (Africa, Americas, Eastern Mediterranean, European, South-East Asia and Western Pacific)
high rates of antimicrobial resistance have been observed in
this pathogen [3].
Ciprofloxacin is the most commonly prescribed
fluoroquinolone for UTIs because it is available in oral
and intravenous preparations [4]. It is well absorbed
from the gastrointestinal tract after oral administration.
It also has a documented safety profile, broad Gram
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negative organism coverage and high urinary excretion
rate [4]. During the last decade the resistance rate of E.
coli to fluoroquinolones such as ciprofloxacin has increased [5]. A 10 year analysis of urinary E. coli specimens in Switzerland, found an increasing trend in
resistance to ciprofloxacin, from 1.8 to 15.9 % [6]. Fluoroquinolones are ranked as one of four of the highest priority critically important antimicrobials [7] as they have
an important role in the treatment of more severe infections, such as septicaemia. Therefore resistance to fluoroquinolones can have serious clinical consequences.
They are one of few available therapies for serious
Salmonella spp. and E.coli infections [5]. Resistance to
fluoroquinolones emerges quickly, and this is likely to be
related to the biology of resistance as well as a direct response to drug pressure [8]. They should therefore be
used with caution and reserved for severe infections,
and preceded by antimicrobial susceptibility testing of
the bacteria involved [5]. The most recent Infectious
Diseases Society of America (IDSA) guidelines recommend that fluoroquinolones should be reserved for
important uses due to their propensity for ecological unfavorable effects of antimicrobial therapy such as the selection of drug-resistant pathogens and colonisation or
infection with multidrug-resistant organisms [9].
Recent prescribing guidelines recommend reserving
ciprofloxacin use for more severe infections and resistance to this agent is increasing prompting further research in this area [6, 10, 11]. Published quantitative
syntheses of overall ciprofloxacin-resistant E. coli UTI
prevalence and incidence in hospital and community settings are absent. This systematic review of observational
studies therefore aims to compare ciprofloxacin resistance in both settings. Knowledge about ciprofloxacin resistance in community- and hospital-acquired E. coli
UTIs will provide information for control of resistant
pathogens. This review also has the potential to provide
a basis for which future interventions can be evaluated.
The findings will, in addition, make available information on ciprofloxacin resistance in various regions of the
world providing some evidence for further regulatory
control of ciprofloxacin use globally.

Methods

Page 2 of 16

Search strategy

We conducted a systematic review of observational (cross
sectional, cohort and case control) studies published in
the last 11 years (2004–2014) reporting on ciprofloxacin
resistance in community- and hospital-acquired E. coli
UTIs. This time limit is based on changes in the microbiology and epidemiology of antimicrobial resistant pathogens which occurred in the past decade with subsequent
changes in treatment regimens and patient outcomes [12].
Reporting of this review complied with the preferred
reporting items for systematic reviews and meta-analyses
(PRISMA) [13].
The electronic bibliographic databases MEDLINE/
PubMed, EMBASE, Cochrane, CINAHL and Scopus were
searched. Searches were conducted for words in the title or
abstract or within the full text of the papers. These included
both keywords only and keywords with medical subject
headings (MeSH) using the search terms ‘resistance’, ‘urinary
tract infection’ and ‘Escherichia coli’ from 1st January 2004
to 31st December 2014 (see Additional file 1). The reference lists of papers identified from the electronic databases
were hand-searched for additional papers.
Inclusion and exclusion criteria

Papers were included if they reported prevalence or incidence rates of ciprofloxacin resistance in community- or
hospital-acquired E. coli UTIs. Papers reporting on urinary
E. coli ciprofloxacin susceptibility in which resistance rate
could be calculated were also included. We included papers involving adults and/or children. Only peer reviewed
manuscripts were considered. Grey material which includes unpublished literature, conference abstracts, letters
to editors, newsletters and reports were excluded. Nonpeer reviewed literature were also excluded. Papers
written in languages other than English were also excluded.
In addition, papers not clearly specifying the setting
(hospital-acquired or community-acquired); drug (ciprofloxacin) or sample (urine) were excluded. Papers that
focused on specific sub-populations (e.g. diabetics and patients with recurrent UTI) were also excluded as these did
not represent the general population. This review included
only papers that used the Centers for Disease Control and
Prevention (CDC) definition of microbiologically confirmed
UTI (≥105 colony forming unit/ml) [14].

Protocol and registration

The protocol for conducting this review has been registered and can be accessed on the International prospective register of systematic reviews (PROSPERO) (available
at http://www.crd.york.ac.uk/prospero/ with registration
number: CRD42014014473). Prior to registration, the
protocol was reviewed by a reviewer external to the
study team. Ethics approval was not sought as this review synthesized data from published studies for which
approval had already been obtained.

Definitions

For the purpose of this review, a study was defined as all
data from a published paper with the only distinction being ‘hospital’ or ‘community’ setting. Therefore, if a single
paper meeting the eligibility criteria reported data on both
settings, they were included as two separate studies.
Community-acquired UTI was defined as positive samples obtained from (i) outpatient clinics; (ii) general practice (GP) clinics; (iii) emergency departments; (iv) within
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48 h of hospital admission or (v) from nursing homes or
residential aged care facilities [15–17].
Hospital-acquired UTI was defined as positive samples
obtained (i) after 48 h of hospital admission or (ii) within
48 h of hospital discharge [15].
Important changes in healthcare delivery over the last
few years have seen some usually inpatient procedures
now more often than not performed on an outpatient
basis [18]. Patients transition freely within sometimes
loosely defined levels of the health care system, for example between long-term care or rehabilitation services,
to acute-care centres [19, 20]. This study only considered
hospital-acquired UTIs as opposed to a wider definition of
healthcare associated UTIs, to avoid this confusion.
Study selection

The titles and abstracts of all papers identified in the electronic databases were examined and assessed for relevance
and appropriateness to the principal objective of the systematic review. Irrelevant studies were excluded. Full texts
of the potentially relevant papers were printed and carefully assessed against the systematic review inclusion and
exclusion criteria. Those not meeting the criteria were excluded. The remaining papers deemed to have data relevant to the systematic review and meta-analysis were
assessed for quality and risk of bias.
The study selection process and other stages of the review were performed by the lead author (OF). At each
stage, 10 % of papers identified were also screened
against the study criteria independently by other authors
(AG, GM and BM). Discrepancies in either the application of inclusion or exclusion of papers, quality assessment or on data extraction were discussed among all
authors to make the final decision.
Data extraction process

Data were extracted by one author (OF) and 10 % of papers eligible for data extraction were independently extracted by another author (AG). Data extraction was
compared between AG and OF demonstrating 100 %
agreement for all items except the study design. This
variable was therefore assessed by all authors. Where
there was missing information on the study design of papers to be included in the meta-analysis, attempts were
made to contact the authors. When there was no response, consensus on the study design was reached by
all authors. Agreement between authors was assessed
using Kappa coefficient. The agreement between all authors in deciding on the study design was 71 % (Kappa
(95 % CI) = 0.429 (0.154–0.703), P Value = 0.003). Papers
for which no agreement could be reached on the design,
based on insufficient information, were assigned as nonclassifiable. Any other missing information in the included papers was recorded as ‘not stated’.

Page 3 of 16

The first author, year of study, country of study, study
setting, age and sex distribution, co-morbidities, sample
size, study design, study aim, antimicrobial susceptibility
testing method, ciprofloxacin resistance rate, risk factors
for ciprofloxacin resistance (i.e. previous antibiotic use)
and mortality data (if reported) were extracted. Where
the ciprofloxacin resistance rate was not available, the
susceptibility rate was used to determine resistance.
Risk of bias in individual studies

Quality and risk of bias of the final papers included
in the review was conducted using a modified version
of the Newcastle-Ottawa Scale (NOS) which is a risk
of bias assessment tool for observational studies recommended by the Cochrane Collaboration [21, 22].
Content validity and inter-rater reliability of this tool
have been established [22]. Studies were rated by
assigning a judgment of ‘Low risk’ of bias, ‘High risk’
of bias, or ‘Unclear risk’ of bias according to published criteria [21].
Statistical analysis

Pooled ciprofloxacin resistance proportions (with 95 %
confidence intervals) in patients with E. coli UTI were
separately calculated and compared between hospital
and community settings using a random-effects metaanalysis model based on DerSimonian and Laird method
[23, 24]. This method incorporates an estimate of the
between-study variation into both the study weights and
the standard error of the estimate of the common effect.
The precision of an estimate from each included study
was represented by the inverse of the variance of the
outcome pooled across all studies. If the value of the
pooled prevalence was within the 95 % CI, then the effect size was statistically significant at the 5 % level (P <
0.05). The heterogeneity among studies was assessed by
using the I2 statistic with a P value of <0.05 considered
statistically significant, and I2 values below 25 % indicating low heterogeneity, 25–75 % moderate heterogeneity
and over 75 % high heterogeneity [25]. Subgroup analyses were done by risk of bias, study duration, age
group, UTI symptoms, world region and economy of
country (categorised as developed and developing using
the World Bank classification [26]). A meta-regression
analysis was used to determine the effect of measured
covariates on the observed heterogeneity in resistance
estimates across studies [23]. Assessment of publication
bias was estimated using funnel plots. Further analysis
was undertaken to examine pooled ciprofloxacin resistance over time using the median study year. For studies
occurring over 2 years, the first year was used; for studies occurring over 4 years, the 2nd year was used; for
those over 6 years, the 3rd year was used. The nonparametric Spearman’s rho correlation coefficient was
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calculated to determine significance in resistance trend
over time. Statistical analyses were undertaken using Stata
statistical softwareversion 13 [27].

Results
Study selection

Electronic database searches identified 15,062 potential
studies and 31 additional studies were identified through
hand searching. After 11,397 duplicates were removed,
3696 articles remained for title and abstract screening.
We assessed 1134 as potentially eligible and retrieved
the full text of these articles. After applying inclusion
and exclusion criteria, 53 papers (5 %) were deemed to
have data relevant to the systematic review and metaanalysis. These 53 papers consisted of 54 studies comprising three hospital-acquired E. coli UTI studies and
51 community-acquired E. coli UTI studies. There was
one paper that compared resistance in both hospital and
community settings hence reported as two studies [15].
The PRISMA flow chart describing the papers identified
from the search strategy and reasons for exclusion is
shown in Fig. 1.
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was 0.27 (95 % CI: 0.240-0.310), compared with 0.38
(95 % CI: 0.360-0.410) in the hospital setting. There was
substantial heterogeneity among the community-setting
studies (I2 = 98.8 %, P < 0.0001), but very little in the hospital ones (I2 = <0.010 %, P = 0.641). Further analysis of
studies reporting on community-acquired E. coli UTI by
region (Fig. 3) showed that Asia had the highest pooled resistance. Analysis by economy based on the World Bank
classification (Fig. 4) showed a higher pooled resistance in
developing countries.
Resistance over time in community-acquired UTI studies

Figure 5 shows the scatter plot of ciprofloxacin resistance
in 47 studies reporting on community-acquired UTI using
the median study year for each study. Four studies did not
provide data on the year(s) the study was conducted and
were excluded from this analysis [29–32]. The results of
the Spearman’s rho correlation test showed a statistically
significant rise in resistance over time (n = 47, rs =
0.431, P = 0.003). Similar findings were observed for developing countries. There was no significant rise in resistance
over time in developed countries.

Study characteristics

Subgroup analyses

Geographically, 53 of the 54 studies were carried out in
Asia (28 %; n = 15), Europe (24 %; n = 13), Middle East
(15 %; n = 8), Africa (13 %; n = 7), North America (11 %;
n = 6) and South America (7 %; n = 4). The remaining
study was conducted in multiple countries [28]. There
were 17 (31 %) studies conducted in developed countries
and 36 (67 %) in developing countries. The majority of
the studies (80 %) followed a cross sectional design. The
duration of studies ranged from 2 months to 84 months
(median = 15.5; IQR = 12.0-30.0). The mean age and sex
proportion of patients with an E. coli UTI were stated in
13 % (n = 7) and 44 % (n = 24) of studies respectively.
Most study populations included patients of both sexes although 19 % (n = 10) included only women. Antimicrobial
susceptibility testing and interpretation was performed
using the disk diffusion method (74 %) and Clinical and
Laboratory Standards Institute (CLSI) criteria (83 %) respectively in most studies. Table 1 provides further details
on the description of the included studies.

Sub-group analysis was conducted within each major
setting. For community-acquired UTI studies (Table 2),
there was a significant difference in the pooled resistance
within each subgroup examined (risk of bias, study duration, economy, region, age group and UTI symptoms).
The subgroup analyses results for studies reporting on
hospital-acquired E. coli UTI (see Additional file 2)
showed no difference in the pooled resistance within the
subgroups examined (region, economy and UTI symptoms). When both settings were compared (see Additional
file 3), there were significant differences noted for risk of
bias (high), study duration (>12 months), economy (developed), region (Americas), age group (adults and children)
and UTI symptoms (P < 0.001). There were no data available on mortality for comparison between settings.

Pooled ciprofloxacin resistance

Figures 2 and 3 show the forest plots of studies reporting on ciprofloxacin resistance in community acquired
E. coli UTI by region and economy, respectively. Figure 4
shows the forest plot of studies reporting on ciprofloxacin
resistance in hospital acquired E. coli UTI. Compared with
the community-setting, resistance to ciprofloxacin in E
coli UTIs was significantly higher in the hospital-setting
(P < 0.001). Overall, the pooled rate for ciprofloxacin resistance in patients with community-acquired E. coli UTIs

Meta-regression analyses

Random effects meta-regression analyses of studies
reporting on community-acquired E. coli UTI showed
that country’s economy (P = 0.008), Asia as a region (P =
0.002), high risk of bias (P = 0.003), year of study (P =
0.020) and studies using only children as the study population (P = 0.030) were the study factors significantly accounting for the observed heterogeneity, responsible for
61 % of the between study variance (Adjusted R2) in ciprofloxacin resistance.
Risk of bias

When studies were assessed for risk of bias using the
Newcastle-Ottawa scale, 30 % (n = 16) were assessed as
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Fig. 1 PRISMA flow diagram of study selection. (*54 studies from 53 papers)

having a low risk of bias; 22 % (n = 12) unclear risk of bias
and 48 % (n = 26) were deemed to have a high risk of bias.
Further analysis of the 16 low risk studies only was consistent with findings reported from the analysis of all studies. An increasing resistance trend over time was also
observed, however this increase did not reach statistical
significance because of reduced statistical power.

Discussion
The findings of this systematic review and meta-analysis
highlight the higher ciprofloxacin resistance in hospitalacquired E.coli UTI when compared to communityacquired UTI. There is also substantial evidence that
ciprofloxacin resistance in community-acquired E. coli
UTI has been increasing in recent years. Resistance was

Study author

Country

Designa

Setting

Risk of bias

Study durationb
(months)

Number of
positive E. coli
UTI samplesc

Number of
ciprofloxacin
resistant E. coli

Proportion resistant
(95 % CI)

Standard error

Weightd (%)

Ahmad, 2012

India

Cross sectional

Community

Unclear

24

318

48

0.15 (0.11, 0.19)

0.02

2.09

Akoachere et al., 2012

Cameroon

Cross sectional

Community

Low

12

43

Akram et al., 2007

India

Cross sectional

Community

High

12

61

11

0.26 (0.13, 0.39)

0.07

1.61

42

0.69 (0.57, 0.80)

0.06

1.70

AlSweih et al., 2005

Kuwait

Cross sectional

Community

High

12

1535

81

0.05 (0.04, 0.06)

0.01

2.15

Al-Tawfiq et al., 2009

Saudi Arabia

Cohort

Community

High

12

2281

592

0.26 (0.24, 0.28)

0.01

2.14

Ansbach et al., 2013

USA

Cross sectional

Community

High

7

98

2

0.02 (−0.01, 0.05)

0.01

2.12

Arabi et al., 2013

Iran

Cross sectional

Community

Low

33

103

23

0.22 (0.14, 0.30)

0.04

1.91

Araujo et al., 2011

Brazil

Cross sectional

Community

Unclear

24

391

36

0.09 (0.06, 0.12)

0.01

2.12

Arslan et al., 2005

Turkey

Cross sectional

Community

Low

5

514

135

0.26 (0.22, 0.30)

0.02

2.09

Astal, 2005

Palestine

Cross sectional

Community

High

6

252

30

0.12 (0.08, 0.16)

0.02

2.09

Azap et al., 2010

Turkey

Cohort

Community

Unclear

12

464

139

0.30 (0.26, 0.34)

0.02

2.08

Bahadin et al., 2011

Singapore

Cross sectional

Community

Unclear

12

90

22

0.24 (0.16, 0.33)

0.05

1.86

Biswas et al., 2006

India

Cross sectional

Community

High

36

354

124

0.35 (0.30, 0.40)

0.03

2.05

Bouchillon et al., 2013

USA

Cross sectional

Community

High

24

723

234

0.32 (0.29, 0.36)

0.02

2.10

Bouchillon et al., 2013

USA

Cross sectional

Hospital

High

24

253

103

0.41 (0.35, 0.47)

0.03

11.83

Dash et al., 2013

India

Cross sectional

Community

Low

30

397

212

0.53 (0.48, 0.58)

0.03

2.05

Dimitrov et al., 2004

Kuwait

Cross sectional

Community

High

84

780

92

0.12 (0.10, 0.14)

0.01

2.13

Farshad et al., 2011

Iran

Cross sectional

Community

Low

12

90

8

0.09 (0.03, 0.15)

0.03

2.01

Ghadiri et al., 2012

Iran

Cross sectional

Hospital

High

24

200

80

0.40 (0.33, 0.47)

0.03

9.41

Gobernado et al., 2007

Spain

Cross sectional

Community

Low

12

2292

418

0.18 (0.17, 0.20)

0.01

2.14

Ho et al., 2010

Hong Kong

Cross sectional

Community

Low

24

271

35

0.13 (0.09, 0.17)

0.02

2.09

Hoban et al., 2011

Multiple countries

Cross sectional

Hospital

High

24

1643

624

0.38 (0.36, 0.40)

0.01

78.76

Ismaili et al., 2011

Belgium

Cohort

Community

High

24

189

5

0.03 (0.00, 0.05)

0.01

2.13

Kashef et al., 2010

Iran

Cross sectional

Community

High

30

578

180

0.31 (0.27, 0.35)

0.02

2.09

Kiffer et al., 2007

Brazil

Cross sectional

Community

Unclear

48

22679

2699

0.12 (0.11, 0.12)

0.002

2.15

Killgore et al., 2004

USA

Case–control

Community

Low

12

120

40

0.33 (0.25, 0.42)

0.04

1.89

Kimando et al., 2010

Kenya

Cross sectional

Community

Unclear

6

92

6

0.07 (0.01, 0.12)

0.03

2.05

India

Cross sectional

Community

High

6

361

260

0.72 (0.67, 0.77)

0.02

2.06

Kurutepe et al., 2005

Turkey

NC

Community

High

72

880

174

0.20 (0.17, 0.22)

0.01

2.12

Lau et al., 2004

Taiwan

Cross sectional

Community

Unclear

13

80

14

0.17 (0.09, 0.26)

0.04

1.89

Ljuca et al., 2010

Bosnia & Herzegovina

Cross sectional

Community

High

36

43

4

0.09 (0.01, 0.18)

0.04

1.87
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Kothari et al., 2008
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Table 1 Description of studies included in meta-analysis

Longhi et al., 2012

Italy

NC

Community

Low

6

154

36

0.23 (0.17, 0.30)

0.03

1.98

Martinez et al., 2012

Colombia

Cross sectional

Community

High

2

102

39

0.38 (0.29, 0.48)

0.05

1.83

Miragliotta et al., 2008

Italy

Cohort

Community

Low

60

2589

422

0.16 (0.15, 0.18)

0.01

2.14

Molina-Lopez et al., 2011

México

Cross sectional

Community

High

48

119

65

0.55 (0.46, 0.64)

0.05

1.86

Moreira et al., 2006

Brazil

Cross sectional

Community

Unclear

15

544

65

0.12 (0.09, 0.15)

0.01

2.12

Murugan et al., 2012

India

Cohort

Community

High

12

204

144

0.71 (0.64, 0.77)

0.03

2.00

Muvunyi et al., 2011

Rwanda

Cross sectional

Community

Low

6

72

23

0.32 (0.21, 0.43)

0.05

1.75

Mwaka et al., 2011

Uganda

Cross sectional

Community

High

NS

27

9

0.33 (0.16, 0.51)

0.09

1.32

Ni Chulain et al., 2005

Ireland

Cross sectional

Community

High

5

723

18

0.02 (0.01, 0.04)

0.01

2.15

Olson et al., 2012

USA

Cross sectional

Community

Unclear

16

95

4

0.04 (0.00, 0.08)

0.02

2.08

Otajevwo, 2013

Nigeria

Cross sectional

Community

High

6

5

4

0.80 (0.45, 1.15)

0.18

0.63

Prakash et al., 2013

India

Cross sectional

Community

Low

NS

23

16

0.70 (0.51, 0.88)

0.10

1.26

Randrianirina et al., 2007

Madagascar

Cross sectional

Community

Low

28

607

100

0.16 (0.14, 0.19)

0.02

2.12

Rani et al., 2011

India

Cross sectional

Community

Unclear

6

208

151

0.73 (0.67, 0.79)

0.03

2.01

Shaifali et al., 2012

India

Cross sectional

Community

Unclear

12

46

28

0.61 (0.47, 0.75)

0.07

1.54

Shariff et al., 2013

India

Cross sectional

Community

High

18

491

160

0.33 (0.28, 0.37)

0.02

2.08

Sire et al., 2007

Senegal

Cross sectional

Community

Low

33

1010

157

0.16 (0.13, 0.18)

0.01

2.13

Sood et al., 2012

India

NC

Community

High

30

214

160

0.75 (0.69, 0.81)

0.03

2.02

Stratchounski et al., 2006

Russia

NC

Community

Low

48

423

18

0.04 (0.02, 0.06)

0.01

2.14

Vellinga et al., 2012

Ireland

Case–control

Community

Low

9

633

78

0.12 (0.10, 0.15)

0.01

2.12

Wang et al., 2014

China

Cross sectional

Community

High

8

129

91

0.71 (0.63, 0.78)

0.04

1.92

Yildirim et al., 2010

Turkey

Cross sectional

Community

Unclear

24

450

85

0.19 (0.15, 0.23)

0.02

2.10

Yolbas et al., 2013

Turkey

Cross sectional

Community

High

12

113

24

0.21 (0.14, 0.29)

0.04

1.93
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Table 1 Description of studies included in meta-analysis (Continued)

a

Non-classifiable design
Not stated
Study denominator
d
Weights are from random effects analysis using DerSimonian-Laird model
b
c
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Urinary E coli resistance to ciprofloxacin by economy: community setting
Study
World Bank Classification: developed economy
Al-Tawfiq et al, 2009, Saudi Arabia
AlSweih et al, 2005, Kuwait
Ansbach et al, 2013, USA
Bahadin et al, 2011, Singapore
Bouchillon et al, 2013, USA
Dimitrov et al, 2004, Kuwait
Gobernado et al, 2007, Spain
Ho et al, 2010, Hong Kong
Ismaili et al, 2011, Belgium
Killgore et al, 2004, USA
Longhi et al, 2012, Italy
Miragliotta et al, 2008, Italy
Ni Chulain et al, 2005, Ireland
Olson et al, 2012, USA
Stratchounski et al, 2006, Russia
Vellinga et al, 2012, Ireland
Subtotal (I-squared = 98.6%, p = 0.000)
.
World Bank Classification: developing economy
Ahmad, 2012, India
Akoachere et al, 2012, Cameroon
Akram et al, 2007, India
Arabi et al, 2013, Iran
Araujo et al, 2011, Brazil
Arslan et al, 2005, Turkey
Astal, 2005, Palestine
Azap et al, 2010, Turkey
Biswas et al, 2006, India
Dash et al, 2013, India
Farshad et al, 2011, Iran
Kashef et al, 2010, Iran
Kiffer et al, 2007, Brazil
Kimando et al, 2010, Kenya
Kothari et al, 2008, India
Kurutepe et al, 2005, Turkey
Lau et al, 2004, Taiwan
Ljuca et al, 2010, Bosnia & Herzegovina
Martinez et al, 2012, Colombia
Molina-Lopez et al, 2011, Mexico
Moreira et al, 2006, Brazil
Murugan et al, 2012, India
Muvunyi et al, 2011, Rwanda
Mwaka et al, 2011, Uganda
Otajevwo, 2013, Nigeria
Prakash et al, 2013, India
Randrianirina et al, 2007, Madagascar
Rani et al, 2011, India
Shaifali et al, 2012, India
Shariff et al, 2013, India
Sire et al, 2007, Senegal
Sood et al, 2012, India
Wang et al, 2014, China
Yildirim et al, 2010, Turkey
Yolbas et al, 2013, Turkey
Subtotal (I-squared = 98.8%, p = 0.000)
.
Overall (I-squared = 98.8%, p = 0.000)

ES (95% CI)

%
Weight

0.26 (0.24, 0.28)
0.05 (0.04, 0.06)
0.02 (-0.01, 0.05)
0.24 (0.16, 0.33)
0.32 (0.29, 0.36)
0.12 (0.10, 0.14)
0.18 (0.17, 0.20)
0.13 (0.09, 0.17)
0.03 (0.00, 0.05)
0.33 (0.25, 0.42)
0.23 (0.17, 0.30)
0.16 (0.15, 0.18)
0.02 (0.01, 0.04)
0.04 (0.00, 0.08)
0.04 (0.02, 0.06)
0.12 (0.10, 0.15)
0.14 (0.10, 0.19)

2.14
2.15
2.12
1.86
2.10
2.13
2.14
2.09
2.13
1.89
1.98
2.14
2.15
2.08
2.14
2.12
33.36

0.15 (0.11, 0.19)
0.26 (0.13, 0.39)
0.69 (0.57, 0.80)
0.22 (0.14, 0.30)
0.09 (0.06, 0.12)
0.26 (0.22, 0.30)
0.12 (0.08, 0.16)
0.30 (0.26, 0.34)
0.35 (0.30, 0.40)
0.53 (0.48, 0.58)
0.09 (0.03, 0.15)
0.31 (0.27, 0.35)
0.12 (0.11, 0.12)
0.07 (0.01, 0.12)
0.72 (0.67, 0.77)
0.20 (0.17, 0.22)
0.17 (0.09, 0.26)
0.09 (0.01, 0.18)
0.38 (0.29, 0.48)
0.55 (0.46, 0.64)
0.12 (0.09, 0.15)
0.71 (0.64, 0.77)
0.32 (0.21, 0.43)
0.33 (0.16, 0.51)
0.80 (0.45, 1.15)
0.70 (0.51, 0.88)
0.16 (0.14, 0.19)
0.73 (0.67, 0.79)
0.61 (0.47, 0.75)
0.33 (0.28, 0.37)
0.16 (0.13, 0.18)
0.75 (0.69, 0.81)
0.71 (0.63, 0.78)
0.19 (0.15, 0.23)
0.21 (0.14, 0.29)
0.34 (0.29, 0.40)

2.09
1.61
1.70
1.91
2.12
2.09
2.09
2.08
2.05
2.05
2.01
2.09
2.15
2.05
2.06
2.12
1.89
1.87
1.83
1.86
2.12
2.00
1.75
1.32
0.63
1.26
2.12
2.01
1.54
2.08
2.13
2.02
1.92
2.10
1.93
66.64

0.27 (0.24, 0.31)

100.00

NOTE: Weights are from random effects analysis
-1.15

0

1.15

Fig. 2 Forest plot of ciprofloxacin resistance in community-acquired E. coli UTI by economy

also found to be significantly higher in developing countries reporting on E. coli UTI in community settings.
Antimicrobial resistance has been described as an international hazard to public health threatening the successful
prevention and treatment of bacterial, viral, parasitic and
fungal infections [3, 33]. As such, research into its

prevention and reduction is very important. Our estimated pooled ciprofloxacin resistance of 27 and 38 % in
community- and hospital-acquired E. coli UTI respectively
could not be compared to any other systematic review
findings because, to our knowledge, this is the first systematic review and meta-analysis comparing ciprofloxacin
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Urinary E coli resistance to ciprofloxacin by country region: community setting
Study
Africa
Akoachere et al, 2012, Cameroon
Kimando et al, 2010, Kenya
Muvunyi et al, 2011, Rwanda
Mwaka et al, 2011, Uganda
Otajevwo, 2013, Nigeria
Randrianirina et al, 2007, Madagascar
Sire et al, 2007, Senegal
Subtotal (I-squared = 85.2%, p = 0.000)
.
Asia
Ahmad, 2012, India
Akram et al, 2007, India
Bahadin et al, 2011, Singapore
Biswas et al, 2006, India
Dash et al, 2013, India
Ho et al, 2010, Hong Kong
Kothari et al, 2008, India
Lau et al, 2004, Taiwan
Murugan et al, 2012, India
Prakash et al, 2013, India
Rani et al, 2011, India
Shaifali et al, 2012, India
Shariff et al, 2013, India
Sood et al, 2012, India
Wang et al, 2014, China
Subtotal (I-squared = 98.6%, p = 0.000)
.
Europe
Arslan et al, 2005, Turkey
Azap et al, 2010, Turkey
Gobernado et al, 2007, Spain
Ismaili et al, 2011, Belgium
Kurutepe et al, 2005, Turkey
Ljuca et al, 2010, Bosnia & Herzegovina
Longhi et al, 2012, Italy
Miragliotta et al, 2008, Italy
Ni Chulain et al, 2005, Ireland
Stratchounski et al, 2006, Russia
Vellinga et al, 2012, Ireland
Yildirim et al, 2010, Turkey
Yolbas et al, 2013, Turkey
Subtotal (I-squared = 98.2%, p = 0.000)
.
Middle East
Al-Tawfiq et al, 2009, Saudi Arabia
AlSweih et al, 2005, Kuwait
Arabi et al, 2013, Iran
Astal, 2005, Palestine
Dimitrov et al, 2004, Kuwait
Farshad et al, 2011, Iran
Kashef et al, 2010, Iran
Subtotal (I-squared = 98.7%, p = 0.000)
.
Americas
Ansbach et al, 2013, USA
Bouchillon et al, 2013, USA
Killgore et al, 2004, USA
Molina-Lopez et al, 2011, Mexico
Olson et al, 2012, USA
Araujo et al, 2011, Brazil
Kiffer et al, 2007, Brazil
Martinez et al, 2012, Colombia
Moreira et al, 2006, Brazil
Subtotal (I-squared = 97.7%, p = 0.000)
.
Overall (I-squared = 98.8%, p = 0.000)

ES (95% CI)

%
Weight

0.26 (0.13, 0.39)
0.07 (0.01, 0.12)
0.32 (0.21, 0.43)
0.33 (0.16, 0.51)
0.80 (0.45, 1.15)
0.16 (0.14, 0.19)
0.16 (0.13, 0.18)
0.20 (0.14, 0.26)

1.61
2.05
1.75
1.32
0.63
2.12
2.13
11.60

0.15 (0.11, 0.19)
0.69 (0.57, 0.80)
0.24 (0.16, 0.33)
0.35 (0.30, 0.40)
0.53 (0.48, 0.58)
0.13 (0.09, 0.17)
0.72 (0.67, 0.77)
0.17 (0.09, 0.26)
0.71 (0.64, 0.77)
0.70 (0.51, 0.88)
0.73 (0.67, 0.79)
0.61 (0.47, 0.75)
0.33 (0.28, 0.37)
0.75 (0.69, 0.81)
0.71 (0.63, 0.78)
0.50 (0.37, 0.63)

2.09
1.70
1.86
2.05
2.05
2.09
2.06
1.89
2.00
1.26
2.01
1.54
2.08
2.02
1.92
28.62

0.26 (0.22, 0.30)
0.30 (0.26, 0.34)
0.18 (0.17, 0.20)
0.03 (0.00, 0.05)
0.20 (0.17, 0.22)
0.09 (0.01, 0.18)
0.23 (0.17, 0.30)
0.16 (0.15, 0.18)
0.02 (0.01, 0.04)
0.04 (0.02, 0.06)
0.12 (0.10, 0.15)
0.19 (0.15, 0.23)
0.21 (0.14, 0.29)
0.16 (0.11, 0.21)

2.09
2.08
2.14
2.13
2.12
1.87
1.98
2.14
2.15
2.14
2.12
2.10
1.93
27.00

0.26 (0.24, 0.28)
0.05 (0.04, 0.06)
0.22 (0.14, 0.30)
0.12 (0.08, 0.16)
0.12 (0.10, 0.14)
0.09 (0.03, 0.15)
0.31 (0.27, 0.35)
0.17 (0.08, 0.25)

2.14
2.15
1.91
2.09
2.13
2.01
2.09
14.52

0.02 (-0.01, 0.05)
0.32 (0.29, 0.36)
0.33 (0.25, 0.42)
0.55 (0.46, 0.64)
0.04 (0.00, 0.08)
0.09 (0.06, 0.12)
0.12 (0.11, 0.12)
0.38 (0.29, 0.48)
0.12 (0.09, 0.15)
0.21 (0.15, 0.27)

2.12
2.10
1.89
1.86
2.08
2.12
2.15
1.83
2.12
18.27

0.27 (0.24, 0.31)

100.00

NOTE: Weights are from random effects analysis
-1.15

0

1.15

Fig. 3 Forest plot of ciprofloxacin resistance in community-acquired E. coli UTI by region

resistance in community- and hospital-acquired E. coli
UTI. However, national data from five WHO regions show
at least 50 % resistance to fluoroquinolones (ciprofloxacin,
norfloxacin or ofloxacin) in E. coli [3]. Data on E. coli in

the WHO report are from various settings and sources
(including blood and urine) hence cannot be directly compared with the results from our systematic review. Another recent review on global fluoroquinolone resistance
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Urinary E coli resistance to ciprofloxacin: hospital setting

%

Study

ES (95% CI)

Weight

Bouchillon et al, 2013, USA

0.41 (0.35, 0.47)

11.83

Ghadiri et al, 2012, Iran

0.40 (0.33, 0.47)

9.41

Hoban et al, 2011, multiple countries

0.38 (0.36, 0.40)

78.76

Overall (I-squared = 0.0%, p = 0.641)

0.38 (0.36, 0.41)

100.00

NOTE: Weights are from random effects analysis
-.468

0

.468

Fig. 4 Forest plot of ciprofloxacin resistance in hospital-acquired E. coli UTI

Ciprofloxacin resistance in community E coli urinary tract infections over time

Proportion of resistance

.8

.6

Spearman's correlation coefficient = 0.431, P value = 0.003

.4

.2

0
1995

2000

2005
Year of study

2010

2015

Fig. 5 Scatter plot of ciprofloxacin resistance in community-acquired UTI by year of study (1998–2012). N = 47 (4 studies excluded due to missing
information on year study was conducted)
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Table 2 Subgroup analyses of pooled ciprofloxacin resistance in community setting
Subgroup

Community Setting N = 51

P value*

Pooled resistance
Risk of bias
Study durationa

Low and unclear n = 28 studies

0.221

High n = 23 studies

0.337

≤12 monthsn = 25 studies

0.323

>12 monthsn = 24 studies

0.219

Economy

Developedn = 16 studies

0.141

Developingn = 35 studies

0.345

Region

Africa, Asia and Middle Eastn = 29 studies

0.361

Europe, North and South American = 22 studies

0.174

Age groupa

Adults and children bn = 24 studies

0.265

Adults onlyn = 19 studies

0.302

Symptomatic and asymptomatic patients n = 11 studies

0.185

Symptomatic patients only n = 40 studies

0.295

UTI symptoms

<0.0001

<0.0001

<0.0001

<0.0001

<0.0001

<0.0001

n = number of studies reporting on community acquired UTI
*Comparing pooled resistance for difference in subgroup in community setting
a
Studies with missing information on this sub-analysis were not included
b
Studies reporting resistance in adults and children or children only

epidemiology reported a range of 2 to 69 % for fluoroquinolone resistance in uncomplicated communityacquired UTI and up to 98 % in complicated cases, with
fluoroquinolone resistance in healthcare associated UTIs
ranging from 6 to 62 % [34]. The findings from our systematic review are within the above reported ranges.
However, the latter ranges were wide and the data were
from a number of different Gram negative uropathogens
and not specifically E. coli accounting for the higher rates.
Available published data show relatively high rates of urinary E. coli resistance to ciprofloxacin [35–41] prompting
the need for a renewed effort in the further prevention of
spread of resistance to this antimicrobial agent.
We found that urinary E. coli resistance to ciprofloxacin was higher in the hospital compared to the community setting. Our finding is comparable to individual
studies which have assessed urinary E.coli resistance to
ciprofloxacin in both, hospital and community settings
[31, 41–45]. However, often studies do not apply the criterion of 48 h post admission used in our systematic review for identifying hospital acquired UTI [45, 46]. The
Canadian national surveillance study (CANWARD), a
large population-based study undertaken from 2007 to
2009, further confirms our finding of higher resistance
in the hospital setting [47]. Inpatients had a significantly
higher urinary E. coli resistance to ciprofloxacin. Similar
findings were reported by Cullen et al. in Dublin [16].
This is not an unusual finding and may be attributed to
the selective pressure resulting from antimicrobial use in
hospital settings [47]. Patients in hospital, already acutely
ill, become more at risk of developing a resistant infection because of potential immune deficiency and relative
high exposure to antimicrobial agents [48]. Furthermore,

hospitalized patients are more likely to be exposed to
practices that result in cross infection or transmission of
organisms. These and other risk factors enable the
spread of resistance. This has significant implications for
patient care as antimicrobial resistance may lead to
treatment failure resulting in death.
The results of our systematic review showed a significant rise in resistance over time in the community setting. This finding is supported by a number of US-based
studies investigating antimicrobial resistance trend in
outpatients. A fivefold increase (from 3 to 17.1 %) in ciprofloxacin resistance was observed from 2000 to 2010 by
Sanchez et al. [17] in comparison with other antibiotics
investigated [49]. Our findings are also consistent with
Blaettler et al. [6] who found that over a 10 year period
(1997–2007), similar to the timeframe for our review, resistance increased significantly for ciprofloxacin from 1.8
to 15.9 % in Switzerland. This increase coincided with a
rise in ciprofloxacin use in Switzerland [6]. These findings suggest that with increase in the use of fluoroquinolones generally over time, resistance ciprofloxacin is
likely to further increase. It is now known that antimicrobial overuse or misuse is a risk factor for the development of AMR [50]. The specific effect of ciprofloxacin
use on the development of its resistance in UTI pathogens is also clearly documented. A recent Irish study involving 72 general practices found higher ciprofloxacin
resistance levels (5.5 %) in practices with 10 prescriptions per month compared with resistance levels of 3 %
in practices with one prescription per month [51]. Wide
spread use of this agent may have thus resulted in a rise in
ciprofloxacin resistance. In the Netherlands and United
States, an association has also been shown between high
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fluoroquinolone prescriptions and a rise in bacterial resistance [52, 53]. Furthermore, changes in antimicrobial prescribing practices have been shown to precede changes in
resistance rates. A study by Gottesman et al. [54] in Israel
found a significant decrease in E. coli resistance to ciprofloxacin following a nationwide restriction on ciprofloxacin use. Resistance decreased from 12 % in the
pre-intervention period to 9 % in the intervention period.
Our results pose a strong argument for the development
of more stringent criteria limiting ciprofloxacin use. In
addition, other strategies such as adequate surveillance
and monitoring, reinforcement of existing infection prevention and control measures as well as new technological
advancement will help reduce the widespread problem of
antimicrobial resistance [55–57] but these aspects are not
within the scope of this paper.
Our finding of a significant rise in resistance over time
also has implications for the development of treatment
guidelines. The national recommendations for first-choice
empiric antibiotic treatment of UTIs vary considerably [5].
In countries like Spain, Taiwan and Turkey, the treatment
choice for uncomplicated UTIs are fluoroquinolones [5, 58,
59]. In 2000, fluoroquinolones were prescribed for treatment of uncomplicated UTIs in Switzerland in 64 % of
cases [60]. There is concern that resistance to ciprofloxacin
resulting from its first-line use may be associated with an
increase in multidrug resistance [61]. The most recent IDSA
guidelines [9] advise using nitrofurantoin, trimethoprimsulphamethoxazole, fosfomycin or pivmecillinam for
first-line treatment of acute uncomplicated cystitis. Fluoroquinolones should be reserved for important uses other
than acute cystitis or used as an alternative only when
these recommended agents cannot be used [9]. We recommend that ciprofloxacin should not be used as a first
line treatment option for UTIs as continuous increases in
resistance to ciprofloxacin further weaken the effectiveness of this drug.
Additional findings from the meta-analysis showed that
resistance was significantly higher in developing countries
compared to developed countries. A major factor accounting for this difference is the use of over the counter or
non-prescription antibiotics which occur commonly in developing countries [62, 63]. Although this review did not
directly consider antimicrobial resistance in relation to prescribing for the included studies, evidence shows that over
the counter or non-prescription use results in unnecessary
and excessive use of antibiotics. Some of the included studies in our review clearly state that there are no restrictions
for over the counter prescribing of antimicrobials within
their countries [29, 64–73]. A recent systematic review investigating global non-prescription antimicrobial use found
that resistance was common in communities with frequent
non-prescription antimicrobial use [74]. Non-prescription
use was highest in Africa, Asia and Middle East at 100, 58
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and 39 % respectively [74]. In our review, further analyses
by region showed that Asia had the highest pooled resistance to ciprofloxacin with a significantly higher resistance
in Africa, Asia and Middle East combined compared with
Europe and the Americas. Our finding is supported by a
recent paper by Dalhoff [75] reporting that fluoroquinolone resistance was highest in the Asia-Pacific region and
moderate to low in Europe and North America. Furthermore, there is evidence to show that countries that have
developed control policies to regulate non-prescription use
have seen a decrease in antimicrobial use and resistance
rates [74]. Based on our findings, we therefore emphasize
the need for the development of policies restricting over
the counter antimicrobial use in countries that do not have
such policies thereby contributing to the prevention of
patient morbidity and mortality associated with resistant
infections. It is noteworthy to mention that another important factor contributing to antimicrobial resistance is
the use of antibiotics in livestock for growth promotion
[76]. Extensive antimicrobial use in food animal production has been associated with antimicrobial resistance globally [76]. This has considerable implications for human
health with the need to protect the efficacy of these antimicrobials to ensure their effectiveness for the treatment of
humans.
A large variation in ciprofloxacin resistance was found
in studies reporting on community-acquired UTI. This
variation highlights the significance of local resistance
monitoring to guide the development of local antibiotic
guidelines. The random effects meta-regression model
confirmed that a number of factors significantly accounted
for the variations in ciprofloxacin resistance. These include economy (developed and developing), Asia as a region, year of study, studies including only children and
studies with a high risk of bias. The first three factors have
been discussed in detail in the preceding paragraphs. We
found that resistance was lower in studies involving only
children. This finding is in line with a number of studies
which have compared resistance in adults and children
showing significantly higher ciprofloxacin resistance in
adults compared to children [77, 78]. Increased age has
also been shown to be significantly associated with ciprofloxacin resistance [6, 47]. Given that children are less exposed to antimicrobials with limited ciprofloxacin use in
the paediatric age group, this finding is expected [77–79].
Although the importance of intrafamilial cross-infection
of resistant pathogens is yet to be confirmed, it has been
suggested that fluoroquinolone resistance may to some
extent be dependent on cross-infection with transfer from
adults to children [78]. Given this assumption, it is necessary to also monitor resistance levels in children to prevent further resistance development in this vulnerable age
group. Other likely causes of higher resistance in adults
may be the greater likelihood of comorbidities with more
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frequent contact with healthcare settings [47]. The last
factor found to account for heterogeneity between studies
was high risk of bias. Most of the studies included in the
review were found to have a high risk of bias as assessed
using the NOS scale. These studies lacked methodological
rigour including absence of the inclusion of possible confounding factors (such as age, sex and previous use of an
antimicrobial) in the design and analysis of the studies.
The poor reporting of observational studies poses limitations for conducting meta-analysis of these studies. Better
presentation of definitions would enable inclusion in systematic reviews of some categories that had to be excluded in this review. Observational studies are more
prone to confounding bias [80] further emphasizing the
need for adherence to reporting guidelines such as such as
that based on the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement
[81] to ensure clear and comprehensive reporting prior to
publication acceptance. The poor quality of many studies
initially retrieved for this review resulted in a large number being excluded. Therefore the information provided in
this systematic review and meta-analysis of 54 observational studies may not sufficiently address ciprofloxacin
resistance globally but may provide satisfactory evidence
to inform future interventions.
In addition, this systematic review highlights the weaknesses in the quality of antimicrobial resistance data that
are being collected in various regions. These weaknesses
have implications for development of effective surveillance systems to monitor resistance globally and strategies to prevent further resistance development. The
need for the implementation of national and global surveillance systems to detect and continuously monitor
AMR cannot be overemphasized. These systems would
enable prospective studies to be conducted and would
play a major role in curtailing the widespread effect of
antimicrobial resistance and help healthcare providers in
deciding on the most appropriate empirical therapy for
UTI to ensure proper management of patients. Governments need to put in place policies to restrict over the
counter use and inappropriate prescribing of ciprofloxacin and other antimicrobials to prevent further development of resistance.
Strengths and limitations

There are a number of notable strengths to our review.
To our knowledge, this is the first systematic review to
compare the overall prevalence of ciprofloxacin resistance in community- and hospital-acquired E. coli UTI.
We undertook a comprehensive literature search process
to identify and screen articles against eligibility criteria.
Given that generic versions of ciprofloxacin were first
marketed at different times in various countries, our
choice of 2004 as the start date was therefore made on

Page 13 of 16

the basis of changes in the epidemiology of antimicrobial
resistant pathogens which had resulted in changes to
treatment regimens. A further strength of this systematic
review is the development of a peer reviewed, registered
protocol prior to undertaking the review. For studies to
be included in the review, they were restricted to those that
used a standard laboratory UTI criterion of ≥105 cfu/mL as
recommended by the CDC. Although applying the internationally recognised CDC criteria may definitely be considered a strength as it ensures the quality and uniformity
of included studies, this criterion limited the number of
hospital-acquired UTI studies included in our systematic
review. Despite this, resistance was still found to be higher
in the hospital setting compared to the community setting
similar to published studies. While lower counts of uropathogens are relevant for acute episodes of uncomplicated
cystitis, the use of different colony counts makes comparison of data between studies difficult. Including all urinary
E.coli isolates was considered but not done because this
existing surveillance criterion (≥105 cfu/mL and 48 h cut
off) is usually applied to defining infections not isolates.
Also, including all isolates carries the risk of including duplicates. This approach poses some degree of ascertainment
bias as our systematic review focuses on laboratory identified UTIs which may not only underestimate the total
number of UTIs but also lead to selection of samples from
complicated cases thereby overestimating resistance. Another limitation is the wide variation of resistance estimates
between studies and the inclusion of studies having substantial clinical and methodological heterogeneity. Visual
inspection of the funnel plot (Fig. 6) showed asymmetry
suggesting evidence of publication bias, with studies reporting high resistance rates being more likely to be published
posing a limitation to this review. Also, the quality and risk
of bias of some of the studies included in the review
were assessed as high. These limitations were addressed
by undertaking a random effects meta-analysis with subsequent subgroup analyses and random effects metaregression to explain the sources of heterogeneity. For
studies in which the design was not stated, the review authors faced difficulties in categorising such studies hence
some of these studies were grouped as non-classifiable.
These studies did not provide clear and explicit information on the methods used for conducting the studies. This
emphasizes the need for implementation and adherence
to clear reporting standards prior to publication of papers.
Furthermore, in some included studies, adjustments were
not made for important confounding factors relevant to
antimicrobial resistance such as antibiotic use and patient
demographics including age and sex. For this systematic
review, studies on samples obtained from emergency department (ED) patients were classified as communityacquired samples. Included papers did not provide any information on whether some of these patients may have
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Fig. 6 Funnel plot of studies included in meta-analysis

returned from a recent hospitalisation and represented to
the ED. Ideally, these should be considered as hospitalacquired infections as some of these patients may have
been discharged in the previous 48 h. For the purpose of
this review and to overcome inherent variations in how individual studies have defined these patients, we classified
all papers reporting on ED patients as communityacquired UTI studies. It was not possible to determine the
potential effect of samples obtained from nursing home or
residential aged care studies on the pooled resistance because this participant group did not meet the inclusion
criteria for analysis. Furthermore, classification of this setting as hospital or community remains controversial. Finally, validity issues may have arisen from the use of
different antimicrobial susceptibility test and interpretation methods with differing breakpoints which tend to
change over the years. To date, there is still no worldwide
consensus on the most suitable antimicrobial susceptibility testing method with the fact that various countries and
even laboratories within the same country use different
tests and interpretative criteria. Subgroup analysis for
AST method was considered but not done because almost
all studies used the disk diffusion method and CLSI
criteria.

Conclusions
Ciprofloxacin resistance in E. coli UTI is increasing. The
use of this antimicrobial agent as empirical therapy for
UTI should be reconsidered and efforts should be made to
limit its use to clinical conditions for which there are clear

therapeutic indications. Policy restrictions on ciprofloxacin
use need to be developed and enforced especially in developing countries that are yet to have such policies put in
place. Further research is needed to describe ciprofloxacin
resistance in hospital-acquired E. coli UTI using widely accepted definitions.
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